Bristol Myers Squibb acquired Mirati, a commercial stage targeted oncology company, for $4.8 billion. Mirati’s assets expand BMS’s portfolio and pipeline and represent an opportunity to grow its oncology franchise. Through this acquisition, BMS adds KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising clinical assets that complement its oncology pipeline and are strong candidates for single agent development and combination strate...